- Home
- TAK
as 02-21-2025 4:00pm EST
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 42.2B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 0.83 | EPS Growth: | 15.39 |
| 52 Week Low/High: | $12.58 - $15.08 | Next Earning Date: | 01-30-2025 |
| Revenue: | $29,124,927,177 | Revenue Growth: | 9.83% |
| Revenue Growth (this year): | 6.36% | Revenue Growth (next year): | 0.55% |
Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
TAK Breaking Stock News: Dive into TAK Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Insider Monkey
7 days ago
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
Zacks
8 days ago
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Leasing Life
10 days ago
BBI announces $31m facility for Shire to enhance asset finance
Pharma Voice
13 days ago
Are orexins the next golden child of neuroscience?
Pharmaceutical Technology
23 days ago
Takeda announces appointment of Julie Kim as CEO
BioPharma Dive
23 days ago
Christophe Weber, veteran Takeda CEO, to retire next year
MT Newswires
23 days ago
Takeda Pharmaceutical Names Julie Kim Chief Executive
Compare TAK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.